Prostate Cancer - Results from #620

Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. July 5, 2024

Focal Therapy in Grade Group 3 Prostate Cancer. July 5, 2024

Association of Genomic Prostate Score at positive margin with recurrence after radical prostatectomy. July 5, 2024

Prostate cancer risk assessment and avoidance of prostate biopsies using fully automatic deep learning in prostate MRI: comparison to PI-RADS and integration with clinical data in nomograms. July 5, 2024

A prostate cancer gastrointestinal transcriptional phenotype may be associated with diminished response to AR-targeted therapy. July 5, 2024

A prospective evaluation of the prostate microbiome in malignant and benign tissue using transperineal biopsy. July 5, 2024

FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer. July 5, 2024

Is There a Place for De-escalating Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer? July 4, 2024

Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy. July 4, 2024

Clinical Impact of Contouring Variability for Prostate Cancer Tumor Boost. July 4, 2024

The role of a radiopaque peri-rectal hydrogel spacer in aiding accurate daily image-guidance for prostate stereotactic radiotherapy. July 4, 2024

Comparative analysis of genetic risk scores for predicting biochemical recurrence in prostate cancer patients after radical prostatectomy. July 4, 2024

Rare pathogenic structural variants show potential to enhance prostate cancer germline testing for African men. July 4, 2024

Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity. July 4, 2024

Predicting Peak Productivity in Urologic Medicare Practice via Work-Relative Value Units July 3, 2024

Full-Life Technologies Granted FDA Fast Track Designation for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer July 3, 2024

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer. July 3, 2024

Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States. July 3, 2024

Social integration and long-term physical and psychosocial quality of life among prostate cancer survivors in the Health Professionals Follow-up Study. July 3, 2024

Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer. July 3, 2024

Page 32 of 1434